DelveInsight’s “Progressive Fibrosing Interstitial Lung Disease Market Insight, Epidemiology and Market Forecast – 2034” report delivers an in-depth understanding of Progressive Fibrosing Interstitial Lung Disease, historical and forecasted epidemiology as well as the Progressive Fibrosing Interstitial Lung Disease market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
Unlock detailed insights into the Progressive Fibrosing Interstitial Lung Disease Market @ Progressive Fibrosing Interstitial Lung Disease Therapeutics Market
Key Takeaways from the Progressive Fibrosing Interstitial Lung Disease Market Report
- Based on secondary analysis, the prevalence of PF-ILD in the US is estimated at 57.82 to 70.30 cases per 100,000 people, highlighting that a significant number of patients with fibrosing lung diseases are at risk of developing a progressive, irreversible course that requires early recognition and specialized care.
- PF-ILD affects both males and females in the US, with prevalence slightly higher in males at about 29 per 100,000 compared to 27 per 100,000 in females, highlighting that this progressive lung condition is not gender-specific but may be somewhat more common in male.
- In France, secondary analysis estimates the prevalence of PF-ILD at about two cases per 10,000 people.
- In the UK, secondary analysis estimates the incidence of PF-ILD at about 15 to 25 cases per 100,000 people.
- PF-ILD represents the progressive fibrosing pattern that can develop in different ILDs, often described as progressive pulmonary fibrosis (PPF). In Japan, idiopathic pulmonary fibrosis is the most common and well-documented type of PF-ILD, with an estimated incidence of about 27 cases per 100,000, highlighting the significant burden of progressive lung scarring in this population.
- The epidemiology of PF-ILD is expected to change during the forecast period (2025–2034).
- The leading Progressive Fibrosing Interstitial Lung Disease Companies such as Boehringer Ingelheim, Bristol-Myers Squibb, FibroGen, Hoffmann-La Roche Ltd, Pliant Therapeutics Inc., United Therapeutics, Vicore Pharma AB and others.
- Promising Progressive Fibrosing Interstitial Lung Disease Therapies such as BMS-986278, AP01, HEC585 Dose B, ENV-101, Nintedanib, Pirfenidone and others.
Visit our website to access the full report and make informed strategic decisions @ Progressive Fibrosing Interstitial Lung Disease Treatment Drugs
Progressive Fibrosing Interstitial Lung Disease Epidemiology Segmentation in the 7MM
- Total Progressive Fibrosing Interstitial Lung Disease Prevalent Cases
- Total Progressive Fibrosing Interstitial Lung Disease Diagnosed Prevalent Cases
- Progressive Fibrosing Interstitial Lung Disease Type-specific Diagnosed Prevalent Cases
- Total Progressive Fibrosing Interstitial Lung Disease Diagnosed Prevalent cases
Download the report to understand which factors are driving Progressive Fibrosing Interstitial Lung Disease Epidemiology Trends @ Progressive Fibrosing Interstitial Lung Disease Prevalence
Marketed Progressive Fibrosing Interstitial Lung Disease Drugs
- OFEV (Nintedanib): Boehringer Ingelheim
OFEV (nintedanib) is an oral multi-targeted tyrosine kinase inhibitor approved by the US FDA for the treatment of PF-ILD. Available in 100 mg and 150 mg capsules, OFEV works by blocking key pathways that drive abnormal lung fibrosis in ILDs. Presented as nintedanib ethanesulfonate (esylate), it has a well-defined chemical structure and is formulated with specific inactive ingredients to ensure stability and absorption. In clinical trials, OFEV has been shown to significantly slow the decline in lung function in patients with PF-ILD, offering an important option for those with otherwise limited treatment choices. It should be taken as directed and is contraindicated in patients with known hypersensitivity to nintedanib or its excipients.
Emerging Progressive Fibrosing Interstitial Lung Disease Drugs
- Nerandomilast (BI 1015550): Boehringer Ingelheim
Nerandomilast is an oral, preferential inhibitor of phosphodiesterase 4B (PDE4B) in development for progressive fibrosing conditions such as PF-ILD. As the first molecule in a new class of PDE4B inhibitors, nerandomilast is designed to target key inflammatory and fibrotic pathways involved in persistent lung scarring. By selectively inhibiting PDE4B, it aims to reduce inflammation while minimizing side effects often seen with non-selective PDE4 inhibitors. If successful, nerandomilast could expand treatment options for patients with PF-ILD who continue to face limited choices beyond current antifibrotics.
- ENV-101 (taladegib): Endeavor Biomedicines
ENV-101 (taladegib) is an investigational oral Hedgehog pathway inhibitor in development for progressive fibrosing conditions such as PF-ILD. By binding to and blocking a key receptor in the Hedgehog signaling pathway, ENV-101 aims to halt the abnormal buildup of myofibroblasts that drive lung fibrosis. This targeted approach may help resolve the unchecked wound-healing response that leads to scarring in the lungs, with the goal of preserving lung volume and function. If successful, ENV-101 could offer a new therapeutic option for patients with PF-ILD who have limited treatment choices today.
Discover key developments and opportunities in the Progressive Fibrosing Interstitial Lung Disease Market @ Progressive Fibrosing Interstitial Lung Disease Market Size
Progressive Fibrosing Interstitial Lung Disease Drugs Uptake
The drug chapter of the Progressive Fibrosing Interstitial Lung Disease pipeline report provides a comprehensive analysis of both marketed drugs and late-stage pipeline drugs for this condition. It delves into the details of clinical trials, pharmacological actions, agreements, collaborations, approvals, patents, and advantages, and disadvantages of each drug, as well as the latest news and press releases related to Acute Pulmonary Embolism.
Progressive Fibrosing Interstitial Lung Disease Companies
Boehringer Ingelheim, Bristol-Myers Squibb, FibroGen, Hoffmann-La Roche Ltd, Pliant Therapeutics, Inc., United Therapeutics, Vicore Pharma AB and others.
Progressive Fibrosing Interstitial Lung Disease Market Outlook
Progressive Fibrosing Interstitial Lung Disease (PF-ILD) consist of a diverse group of interstitial lung diseases (ILDs) characterized by a similar clinical phenotype of accelerated respiratory failure, frequent disease exacerbation and earlier mortality. ILD and its progressing forms, form a substantial proportion of disabling chronic lung disease leading to significant morbidity and mortality. From the current treatment market scenario, Nintedanib is the only approved treatment in the chronic fibrotic ILDs in the 7MM. Myriads of patients with PF-ILDs are currently orphan of evidence-based treatments and are left with options of receiving corticosteroids and/or off-label immunosuppressive therapies with variable outcomes and are the mainstay of treatment in PF-ILDs. These unmet treatment gaps accentuates the launch of emerging therapies.
Download DelveInsight’s Progressive Fibrosing Interstitial Lung Disease Market report today @ Progressive Fibrosing Interstitial Lung Disease Clinical Trials
Scope of the Progressive Fibrosing Interstitial Lung Disease Market Report
- Coverage- 7MM
- Study Period- 2020-2034
- Progressive Fibrosing Interstitial Lung Disease Companies- Boehringer Ingelheim, Bristol-Myers Squibb, FibroGen, Hoffmann-La Roche Ltd, Pliant Therapeutics, Inc., United Therapeutics, Vicore Pharma AB and others.
- Progressive Fibrosing Interstitial Lung Disease Therapies- BMS-986278, AP01, HEC585 Dose B, ENV-101, Nintedanib, Pirfenidone and others.
- Progressive Fibrosing Interstitial Lung Disease Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
- Progressive Fibrosing Interstitial Lung Disease Unmet Needs, KOL’s views, Analyst’s views, Progressive Fibrosing Interstitial Lung Disease Market Access and Reimbursement
Table of Contents
- Key Insights
- Progressive Fibrosing Interstitial Lung Disease Market Report Introduction
- Country-wise Progressive Fibrosing Interstitial Lung Disease Market Overview at a Glance
- Progressive Fibrosing Interstitial Lung Disease Market Overview by Therapeutic Class
- Methodology of Progressive Fibrosing Interstitial Lung Disease Epidemiology and Market
- Progressive Fibrosing Interstitial Lung Disease Executive Summary
- Key Events
- Progressive Fibrosing Interstitial Lung Disease Disease Background and Overview
- Progressive Fibrosing Interstitial Lung Disease Epidemiology and Patient Population
- Progressive Fibrosing Interstitial Lung Disease Patient Journey
- Progressive Fibrosing Interstitial Lung Disease Marketed Drugs
- Progressive Fibrosing Interstitial Lung Disease Emerging Drugs
- Progressive Fibrosing Interstitial Lung Disease: Market Analysis
- Key Opinion Leaders’ Views
- Progressive Fibrosing Interstitial Lung Disease SWOT Analysis
- Progressive Fibrosing Interstitial Lung Disease Unmet Needs
- Progressive Fibrosing Interstitial Lung Disease Market Access and Reimbursement
- Appendix
- Progressive Fibrosing Interstitial Lung Disease Report Methodology
- DelveInsight Capabilities
- Disclaimer
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
